A B Lifestyle (ABLBL)

Fast Grower

FairStock Score: 32/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Current Price₹88.77
Market Cap₹10,782.34 Cr
P/E Ratio61.22
ROCE0%
ROE—%
Dividend Yield0.56%
Profit Growth20%
Debt/Equity2.14
Sales Growth11.1%
Free Cash Flow₹1,283 Cr
Promoter Holding46.6%
52-Week Range₹81.56 — ₹150.79
SectorRetailing
Book Value₹11.57

Strengths

Concerns

AI Analysis

At ₹105.99, A B Lifestyle carries a market cap of ₹12,459 Cr, trading at 70.53 times earnings and 9.47 times book value. That is not a Graham price. The 66.66% profit growth looks exciting, but sales only grew 9.58%, so margins are doing the heavy lifting. In the latest quarter, it earned ₹69 Cr on ₹2,343 Cr of sales—a thin margin. With debt/equity at 2.67 and ROCE showing 0.00%, I do not see the capital efficiency that defines a wonderful business. A retailer without a clear moat needs prudent leverage; this one appears to have too much. The Piotroski F-Score of 6/9 is acceptable, and free cash flow of ₹1,283 Cr is welcome, but that cash must be used to pay down debt before I fully trust it. Return on equity is unavailable, and no dividend is paid. Promoter holding of 46.60% does align interests, but good ownership cannot cure a weak balance sheet. The FairStock Score of 36/100 matches my caution. If I apply Graham's discipline, I require a margin of safety. At 70 times earnings with a PEG of 1.85, the market is paying a rich price for a business whose sales growth is under 10%. Profit growth of 66.66% may reverse as retail margins stay volatile. This looks like a fast grower in price, not necessarily in quality. I would put it on the watch list, not in the portfolio. I need evidence of debt reduction, stable returns on capital, and sustained profit growth before I pay this valuation. Numbers alone do not make a bargain; the balance sheet and earnings quality must support it. Here, they do not.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer